Rezolute, Inc. provided a positive interim update on its ongoing open-label Phase 3 study (upLIFT) for its drug candidate, ersodetug, in treating tumor hyperinsulinism (HI). The study has reached 50% enrollment, and a significant majority of participants have already met the primary endpoint, demonstrating the drug's potential efficacy. The company anticipates releasing topline results for the fully enrolled study in the second half of 2026.
Key Details
- Primary Endpoint Met: 6 of the 8 enrolled participants met the primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements. These 6 participants also completely discontinued intravenous glucose.
- Enrollment Status: The study has enrolled 8 of a planned 16 participants, marking 50% completion.
- Safety Profile: Ersodetug has been well-tolerated in the study to date, with no drug-related adverse events reported.
- Timeline: Topline results from the fully enrolled upLIFT study are expected to be announced in the second half of 2026.